Abridge vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Pittsburgh ambient clinical AI (founded by cardiologist) at $5.3B valuation Jun 2025; $800M total ($300M a16z/Khosla Series E) deployed at UPMC 12K clinicians, Mayo Clinic, Johns Hopkins competing with Nuance DAX for physician documentation.
About
Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led by Andreessen Horowitz and Khosla Ventures at a $5.3 billion valuation, following a $250 million Series D just four months prior at a $2.8 billion valuation — providing physicians, nurses, and care teams at 150+ health systems with AI that automatically converts patient-clinician conversations into structured clinical notes, saving physicians an average of 3 hours daily and generating high-quality documentation from UPMC (scaling to 12,000 clinicians enterprise-wide), Mayo Clinic, Johns Hopkins, and Emory Healthcare. Abridge's AI is trained on a proprietary dataset of over 1.5 million medical encounters, delivering specialty-specific documentation through deep Epic EHR integration. Founded in 2018 by cardiologist Dr. Shiv Rao.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.